B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2016

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2016
Published Aug 10, 2016
147 pages — Published Aug 10, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2016, provides an overview of the B-Cell Chronic Lymphocytic Leukemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for B-Cell Chronic Lymphocytic Leukemia and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of B-Cell Chronic Lymphocytic Leukemia
- The report reviews pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved B-Cell Chronic Lymphocytic Leukemia therapeutics and enlists all their major and minor projects
- The report assesses B-Cell Chronic Lymphocytic Leukemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players an

  
Source:
Document ID
GMDHC8339IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents27
  List of Tables71
  List of Figures81
Introduction91
  Global Markets Direct Report Coverage91
B-Cell Chronic Lymphocytic Leukemia Overview101
Therapeutics Development112
  Pipeline Products for B-Cell Chronic Lymphocytic Leukemia Overview111
  Pipeline Products for B-Cell Chronic Lymphocytic Leukemia Comparative Analysis121
B-Cell Chronic Lymphocytic Leukemia Therapeutics under Development by Companies132
B-Cell Chronic Lymphocytic Leukemia Therapeutics under Investigation by Universities/Institutes151
B-Cell Chronic Lymphocytic Leukemia Pipeline Products Glance163
  Late Stage Products161
  Clinical Stage Products171
  Early Stage Products181
B-Cell Chronic Lymphocytic Leukemia Products under Development by Companies192
B-Cell Chronic Lymphocytic Leukemia Products under Investigation by Universities/Institutes211
B-Cell Chronic Lymphocytic Leukemia Companies Involved in Therapeutics Development2224
  AB Science SA221
  Aduro BioTech, Inc.231
  Amgen Inc.241
  Celgene Corporation251
  Cell Source, Inc.261
  Dynavax Technologies Corporation271
  Eisai Co., Ltd.281
  Elsalys Biotech SAS291
  F. Hoffmann-La Roche Ltd.301
  iDD biotech SAS311
  Immunomedics, Inc.321
  Johnson &Johnson331
  Juno Therapeutics Inc.341
  Lymphocyte Activation Technologies, S.A.351
  MedImmune, LLC361
  MEI Pharma, Inc.371
  Millennium Pharmaceuticals Inc381
  Molecular Templates Inc.391
  Noxxon Pharma AG401
  Ono Pharmaceutical Co., Ltd.411
  Regeneron Pharmaceuticals Inc421
  Sunesis Pharmaceuticals, Inc.431
  TheraMAB LLC441
  Unum Therapeutics, Inc.451
B-Cell Chronic Lymphocytic Leukemia Therapeutics Assessment4610
  Assessment by Monotherapy Products461
  Assessment by Combination Products471
  Assessment by Target482
  Assessment by Mechanism of Action502
  Assessment by Route of Administration522
  Assessment by Molecule Type542
Drug Profiles5685
  202-b Drug Profile562
  AB-8779 Drug Profile581
  alemtuzumab biosimilar Drug Profile591
  alisertib Drug Profile605
  AMG-319 Drug Profile652
  BB-001 Drug Profile671
  BION-1301 Drug Profile681
  Cellular Immunotherapy for Chronic Lymphocytic Leukaemia Drug Profile691
  Cellular Immunotherapy for Hematological Malignancies Drug Profile701
  Cellular Immunotherapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies Drug Profile712
  Cellular Immunotherapy to Activate CD40L and to Target CD19 for B-Cell Malignancies Drug Profile732
  Cellular Immunotherapy to Activate IL-12 and to Target CD19 for B-Cell Malignancies Drug Profile752
  Cellular Immunotherapy to Target CD16 for B-Cell Non-Hodgkin Lymphoma and B-Cell Chronic Lymphocytic Leukemia Drug Profile771
  Cellular Immunotherapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia Drug Profile781
  Cellular Immunotherapy to Target CD19 for B-Cell Malignancies Drug Profile791
  Cellular Immunotherapy to Target CD19 for Oncology Drug Profile801
  Cellular Immunotherapy to Target CD19 for Oncology Drug Profile811
  Cellular Immunotherapy to Target CD19 for Oncology Drug Profile821
  durvalumab Drug Profile8310
  E-7449 Drug Profile931
  IDD-001 Drug Profile941
  IDD-002 Drug Profile951
  JNJ-64052781 Drug Profile962
  lenalidomide Drug Profile9814
  MAT-303 Drug Profile1121
  ME-401 Drug Profile1132
  mRNA ACTR + rituximab Drug Profile1152
  MT-3724 Drug Profile1172
  olaptesed pegol Drug Profile1194
  ONO-4059 Drug Profile1232
  REGN-1979 Drug Profile1251
  SD-101 Drug Profile1263
  SNS-062 Drug Profile1292
  TAB-08 Drug Profile1312
  tocilizumab Drug Profile1338
B-Cell Chronic Lymphocytic Leukemia Dormant Projects1413
B-Cell Chronic Lymphocytic Leukemia Discontinued Products1441
B-Cell Chronic Lymphocytic Leukemia Product Development Milestones1451
  Featured News &Press Releases1451
    Apr 06, 2015: Juno Therapeutics Announces Patent Litigation Settlement1451
    Nov 15, 2011: TheraMAB launches Phase I clinical trial of first-in-class agonistic monoclonal antibody TAB08 in Russia1451
Appendix1462
  Methodology1461
  Coverage1461
  Secondary Research1461
  Primary Research1461
  Expert Panel Validation1461
  Contact Us1461
  Disclaimer1471

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2016" Aug 10, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/B-Cell-Chronic-Lymphocytic-Leukemia-Pipeline-Review-H2-2016-2088-16347>
  
APA:
Global Markets Direct - Market Research. (2016). B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2016 Aug 10, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/B-Cell-Chronic-Lymphocytic-Leukemia-Pipeline-Review-H2-2016-2088-16347>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.